Ebola Stocks Surge On First Ebola Case In New York

The biotech space has been the subject of huge movements in the recent days with the confirmation of the first Ebola case in New York City, of a doctor returning from Guinea. Search for anyone who might have come into contact with the doctor has already started. Lakeland Industries, Inc. (NASDAQ:LAKE) and Alpha Pro Tech, Ltd. (NYSEMKT:APT), makers of protective gears for contagious viruses are some of the stocks that have continued to benefit from the uncertainty surrounding the virus.

Doctor Craig Spencer has been put under quarantine at the Bellevue Hospital center with three other people he had come into contact with. Infected persons only become dangerous of spreading the virus when they start showing symptoms of the virus and contagious, when the viral load in their body builds up. City officials have already stated that at the time Dr. Spencer was traveling around the city he had not reached the symptomatic stage that poses a great danger in terms of spreading the disease to other people.

Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) was also surging in the market after stating it was developing a new candidate for the Ebola virus. The announcement came as a surprise as the company also has another drug, TKM-Ebola that is currently undergoing expedited trials. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) with its experimental Ebola drug BCX 4430 was also surging on the confirmation of the first Ebola case in New York.

Dr. Spencer has already told officials that he monitored his body temperatures twice a day and did not believe that the protective gear he wore while attending to patients in Guinea had been breached in any way. DR. Spencer was part of Doctors Without Borders that treated patients in Africa. Hospitals in New York have been preparing for the appearance of the virus especially after Dallas reported its first casualty.

NewLink Genetics Corp (NASDAQ:NLNK), which recently signed a licensing deal with Switzerland-based Roche, has, on the other hand, been registering mixed reaction in the market. The company has already confirmed that it has started shipping its experimental Ebola virus vaccine to be used to avert a further spread of the virus.

Chimerix Inc. (NASDAQ:CMRX) whose Ebola drug failed to heal an earlier patient in the U.S continues to surge in the market with the confirmation of the first Ebola case in New York. Ibio Inc. (NYSEMKT:IBIO) has also been recording mixed reactions in the market mostly depending on the news around the deadly virus. The company is believed to have partnered with Zmapp for an Ebola drug that is believed to be the most advanced.

GlaxoSmithKline plc (ADR) (NYSE:GSK) and Johnson & Johnson (NYSE:JNJ) have partnered to speed up the development of what they believe could be the utmost remedy of the Ebola menace. The two companies are reportedly planning to combine their resources, as well as vaccine candidates. GSK has already started its human trials in the U.K hoping to develop enough doses by the end of the year.

About the Author

Laurie, a long-time member of the US Markets Daily general assignment reporter who has covered a variety of subjects from breaking news to investigative features, from stock markets to politics, and from neighborhood small business to global warming.

Leave A Response